Safety and efficacy outcomes of study groups in full cohort and matched cohort
| Full cohort | Matched cohort | |||||
| No IVT | IVT | P value | No IVT | IVT | P value | |
| Outcome | ||||||
| Any hemorrhage | 101 (41.4) | 58 (42.3) | 0.853 | 42 (38.5) | 45 (42.1) | 0.598 |
| Significant intracerebral hemorrhage* | 32 (13.1) | 23 (16.9) | 0.306 | 17 (15.6) | 20 (18.9) | 0.525 |
| Parenchymal hemorrhage type 2† | 23 (71.8) | 16 (69.5) | 11 (64.7) | 15 (75) | ||
| Final mRS, median (IQR) | 5 (3) | 4 (4) | 0.185 | 4 (3) | 4 (4) | 0.913 |
| mRS 0–2 | 38 (17.4) | 36 (27.3) | 0.02 | 23 (23.2) | 27 (26) | 0.652 |
| Successful reperfusion‡ | 213 (84.2) | 112 (78.9) | 0.184 | 93 (82.3) | 90 (81.1) | 0.813 |
*Includes parenchymal hemorrhage type 2 and symptomatic intracerebral hemorrhage.
†() Represent percentage of all significant intracerebral hemorrhage.
‡Defined as mTICI 2b-3.
IVT, intravenous thrombolysis; mRS, modified Rankin Scale; mTICI, modified Treatment In Cerebral Ischemia.